Incyte Stock Plummets; Why Jakafi Couldn’t Outweigh Opzelura Disappointment

Incyte stock tumbled below its 200-day line Tuesday after sales of the company’s new skin treatment lagged the Street’s second-quarter expectations. X During the June quarter, Opzelura gen...

Bio-Rad And Other ‘Balance Sheet Powerhouse’ Stock Buys

Headquarters of Dolby Laboratories, the only company to make the Balance Sheet Powerhouses list 11 … [+] times. (Photo by Smith Collection/Gado) Getty Images For the past half dozen years, inves...